Skip to content
Open access

A Metabolic Cluster–Derived Risk Model for Prognostic Stratification, Immunometabolic Profiling, and Therapeutic Sensitivity Prediction in Prostate Cancer

Oct 2026 · Cancer Management and Research · Vol 18 · 0 citations · 40 references
Medicine

TL;DR

This metabolic cluster–derived three-gene model may support prognostic stratification and characterization of immunometabolic heterogeneity in prostate cancer and provide a rationale for further investigation of potential treatment strategies.

Abstract

Purpose Metabolic reprogramming is a hallmark of prostate cancer; however, the clinical utility of metabolism-related genes for prognostic stratification remains limited. Patients and Methods Prostate cancer patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were stratified into metabolism-associated clusters based on metabolism-related gene expression. Genes differentially expressed between clusters were used to construct a prognostic risk model via least absolute shrinkage and selection operator (LASSO) regression. Associations with clinicopathological features, genomic alterations, metabolic activity, immune status, and therapeutic response were systematically evaluated. Computational analyses included tumor immune dysfunction and exclusion (TIDE) and the immunophenoscore for predicting immunotherapy response, pRRophetic and CellMiner for assessing drug sensitivity, and the Connectivity Map for screening candidate compounds. Exploratory assessments were performed using immunohistochemistry (IHC) in a 20-patient cohort with follow-up data and quantitative polymerase chain reaction (qPCR) in an independent 14-patient cohort. Results Two metabolism-associated clusters with distinct survival outcomes and molecular features were identified. A three-gene signature stratified patients into high- and low-risk groups, with the high-risk group showing poorer survival, greater tumor aggressiveness, elevated tumor mutational burden and microsatellite instability, and enhanced metabolic pathway activity. This group also exhibited an immunosuppressive microenvironment and was predicted to have reduced responsiveness to some immunotherapies and endocrine therapies, along with increased resistance to specific chemotherapeutic agents. In silico analyses suggested several candidate small molecules for further evaluation in the high-risk group. The IHC- and qPCR-based exploratory experiments showed associations between the derived scores and clinicopathological features, providing preliminary support for the transcriptomic signature. Conclusion This metabolic cluster–derived three-gene model may support prognostic stratification and characterization of immunometabolic heterogeneity in prostate cancer. The observed associations between metabolic heterogeneity and computationally predicted therapeutic sensitivity provide a rationale for further investigation of potential treatment strategies.

Read PDF

Similar papers

Open access Oct 2026

Immune–metabolic heterogeneity and prognostic associations in breast cancer: development of an eight-gene risk model and preliminary functional characterization of NAT2

Breast cancer is highly heterogeneous, and immune–metabolic interactions within the tumor microenvironment may contribute to differences in clinical outcome. In this study, transcriptomic, clinical, and somatic mutation data from TCGA-BRCA were analyzed, and the prognostic model was evaluated in GSE199633, a retrospe...

Yu-Chen Li, Shao-Chao Zhan, Ting Li et al. · 0 citations
Open access Oct 2026

Tryptophan metabolism-derived prognostic signature: A potential biomarker for risk stratification and exploratory immunotherapy relevance analysis in prostate cancer.

ObjectiveProstate cancer (PCa) lacks reliable biomarkers to distinguish indolent from aggressive tumors. Tryptophan metabolism (TM) participates in regulating tumor immunity and malignant progression, yet its prognostic relevance in PCa remains poorly characterized.MethodsTranscriptomic and clinical data of TCGA-PRAD c...

An-Ding Gao, Yi-Chen Xu, Ting-Ting Wang et al. · 0 citations
Open access Jan 2026

Identification of Immuno‐Diagnostic and Therapeutic Markers in Tumors and Inflammatory Diseases Based on Single‐Cell and Machine Learning Methods

Background Chemotherapy is the mainstay of systemic treatment for colorectal cancer (CRC), but drug resistance and tumor heterogeneity markedly limit survival. Mitochondrial metabolism is increasingly recognized as a regulator of tumor progression, immune contexture, and therapeutic response. However, the prognostic re...

Jin-Fen Tang, Deng-Gao Yuan, Zhou Wu et al. · 0 citations
Open access Jan 2026

Identification of a Novel Subtype‐Derived Prognostic Signature Based on Nucleotide Metabolism‐Related Molecular Classification for Predicting Lung Adenocarcinoma Prognosis

A subtype‐derived prognostic signature based on nucleotide metabolism‐related molecular classification with potential value for LUAD risk stratification is identified and exploratory evidence linking signature genes to tumor immune features and cellular phenotypes is provided.

Yue Shi, Shan-Shan Li, Lin Zhao et al. · 0 citations
Open access Oct 2026

Bioinformatic and Proteomic Analysis of Potential Prognostic Biomarkers of Glioblastoma

Introduction . Glioblastoma is characterized by marked molecular heterogeneity and aggressive biologic behavior, which requires reliable molecular biomarkers for prognostic stratification. The aim of this study is to identify potential prognostic biomarkers for glioblastoma through integrated bioinformatic and prote...

I. Gareev, O. Beylerli, S. Roumiantsev · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.